Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Olaratumab ± Doxorubicin in Japanese Patients With Advanced Solid Tumors
jRCT2080222784Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaratumab in soft tissue sarcoma (STS) and Nonhematologic neoplasms (2 cohorts), sponsored by Eli Lilly and Company. Started Mar 2015; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080222784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222784.